Monitoring Noxious Events Using EEG-Derived Pain IndicesMO-NOXNCT07413848
qNOX Response to Nociceptive Motor Events During Procedural Sedation
An observational study of Monitoring Noxious Events Using EEG-Derived Pain Indices and Procedural Sedation and Analgesia, run by Ankara University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational study is to evaluate whether the CONOX monitor can detect pain during sedation in patients undergoing urological procedures. The main questions it aims to answer are: Does the qNOX index respond to pain-related motor responses during urological procedural sedation? Does the qNOX index… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Monitoring Noxious Events Using EEG-Derived Pain Indices, Procedural Sedation and Analgesia, Monitored Anesthesia Care
- Type of treatment
- Injection or infusion
- How many people
- 120 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 14 Jan 2026to 30 May 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients (≥18 years) scheduled for elective urological procedures under monitored anesthesia care at Ankara University Faculty of Medicine. Patients will undergo standard procedural sedation with propofol target-controlled infusion and fentanyl, maintaining spontaneous ventilation without neuromuscular blockade.
Who may be able to join
- Age 18 years or older
- Scheduled for elective diagnostic or therapeutic urological procedures (cystoscopy, ureteroscopy, prostate biopsy, intradetrusor botulinum toxin injection) under monitored anesthesia care
- Able to provide written informed consent
Who cannot join
- Known central neurological disease (epilepsy, Alzheimer's disease, Parkinson's disease, stroke) or history of brain surgery
- Body Mass Index (BMI) ≥35 kg/m²
- Known allergy to anesthetic agents used in the study (propofol, fentanyl, lidocaine)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Ankara University
Ankara, Altındağ, 06230
About this study
Official title: Performance of the CONOX Monitor Without Neuromuscular Blockade: qCON and qNOX Responses to Nociceptive Motor Events During Procedural Sedation
The goal of this observational study is to evaluate whether the CONOX monitor can detect pain during sedation in patients undergoing urological procedures. The main questions it aims to answer are:
Does the qNOX index respond to pain-related motor responses during urological procedural sedation? Does the qNOX index show greater responsiveness to painful episodes compared to blood pressure and heart rate? Participants undergoing urological procedures (such as cystoscopy) under sedation as part of their regular medical care will have continuous brain activity monitoring with the CONOX device. All monitoring displays (CONOX monitor, vital signs monitor, and target-controlled infusion pump) will be video-recorded throughout the procedure to capture synchronized data including qCON, qNOX, EMG, heart rate, blood pressure, oxygen saturation, and drug concentrations. Researchers will analyze the relationship between these indices and spontaneous movements triggered by painful stimulation to evaluate the monitor's performance compared to traditional vital signs.
Read the detailed description
STUDY RATIONALE
Adequate monitoring of sedation depth and nociception is essential during monitored anesthesia care (MAC). While processed EEG monitors assess hypnotic depth, monitoring pain remains challenging. The CONOX monitor uniquely provides two indices: qCON for sedation depth and qNOX for nociception probability.
Most CONOX studies have used neuromuscular blockade, which prevents motor responses and limits validation of the qNOX index against observable pain reactions. Furthermore, data during procedural sedation and MAC is limited. The absence of neuromuscular blockade during MAC allows studying the relationship between qNOX values and actual pain-triggered motor responses, providing a concrete reference for nociception assessment.
This study evaluates whether an EEG-based nociception index can reliably detect pain when motor responses are not suppressed. If the qNOX index demonstrates adequate performance, it could provide clinicians with a tool for optimizing analgesic administration while minimizing opioid consumption.
STUDY DESIGN
This is a prospective, observational, single-arm cohort study evaluating CONOX monitor performance during procedural sedation without neuromuscular blockade at Ankara University Faculty of Medicine. The study involves no interventions beyond standard clinical care.
The study will enroll 120 adult patients (≥18 years) undergoing elective urological procedures (cystoscopy, ureteroscopy, transurethral resection) under MAC. These procedures involve intermittent painful stimulation and typically do not require neuromuscular blockade. Patient recruitment and data collection will occur over 4 months, followed by 2 months for analysis.
Processed EEG monitoring is part of standard practice in our department. The CONOX monitor will be used for all enrolled patients. The only study-specific procedure is video recording of monitoring displays (not patients) for subsequent analysis.
METHODS
Anesthesia Protocol:
Patients receive standard ASA monitoring. Anesthesia consists of intravenous fentanyl (1 mcg/kg) followed by propofol target-controlled infusion (TCI) using the Eleveld model. Initial target effect-site concentration is 1.5 mcg/mL, titrated to achieve adequate sedation depth (MOAAS ≤1). Patients maintain spontaneous ventilation with airway support as needed. No neuromuscular blockade is used.
Monitoring and Data Collection:
The CONOX monitor continuously records qCON (hypnotic depth), qNOX (nociception), EMG (electromyographic activity), and burst suppression ratio. Standard monitors record ECG, blood pressure, heart rate, SpO₂, and capnography. The TCI pump displays real-time propofol effect-site concentration.
All monitoring displays are video-recorded throughout procedures to capture synchronized data for post-hoc analysis. Researchers provide verbal timestamps to mark clinical events (drug administration, procedure start, motor responses). Videos capture only monitor screens, not patient images.
Primary Endpoint:
The primary endpoint is change in qNOX index from baseline to peak during spontaneous motor responses triggered by surgical stimulation. Motor responses include extremity/trunk movements, facial grimacing, or vocalization, identified by real-time clinical observation.
Data Analysis:
Video recordings are systematically reviewed to extract monitoring values at baseline and during clinical events. For motor response events, peak values and time-to-peak are recorded for each parameter.
STATISTICAL ANALYSIS
Power analysis determined 30 motor response events are required for paired t-test comparing baseline versus peak qNOX (alpha=0.05, power=0.95). Based on estimated 25% incidence and accounting for potential data loss, 120 patients will be enrolled.
Primary analysis uses paired t-test (or Wilcoxon test if non-normal) to compare qNOX at baseline versus during motor responses. ROC curve analysis evaluates discriminative ability of qNOX, heart rate, and blood pressure for predicting motor responses. Secondary analyses include correlation analyses and repeated measures analysis for induction/emergence dynamics. Statistical significance: p<0.05 (two-tailed).
ETHICS AND SAFETY
This observational study involves no interventions beyond standard care. All management decisions follow routine clinical practice. The study has ethics approval from Ankara University Faculty of Medicine Clinical Research Ethics Committee. Written informed consent is obtained from all participants. The study follows Declaration of Helsinki and Good Clinical Practice guidelines.
- Conditions
- Monitoring Noxious Events Using EEG-Derived Pain Indices, Procedural Sedation and Analgesia, Monitored Anesthesia Care
- Keywords
- EEG Monitoring, CONOX Monitor, qNOX Index, qCON Index, Target Controlled Infusion, Procedural Sedation, Propofol
- Medical subject headings
- Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Procedural Sedation with CONOX Monitoring | Adult patients undergoing elective urological procedures under monitored anesthesia care with continuous CONOX monitoring. All patients receive standard procedural sedation with propofol target-controlled infusion (Eleveld model) and fentanyl (1 mcg/kg), maintaining spontaneous ventilation without neuromuscular blockade. The CONOX monitor continuously records qCON, qNOX, and EMG indices throughout the procedure. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Quantium Nociception Index (qNOX) During Motor Responses to Noxious Stimulation
The Quantium Nociception Index (qNOX) is an electroencephalography-derived dimensionless index ranging from 0 to 99. The magnitude of change from baseline to peak qNOX value during spontaneous motor response episodes will be measured. Greater absolute change indicates better discriminative performance of the qNOX index in detecting nociception-evoked motor responses.
Measured: During the procedure (approximately 15-60 minutes per patient)
Secondary outcomes (4)
Comparison of qNOX Responsiveness Versus Hemodynamic Parameters During Motor Responses
Magnitude of change in qNOX index compared to changes in heart rate, mean arterial pressure and SPI during motor responses to noxious stimulation. Assessed by comparing percentage change from baseline for each parameter.
Measured: During motor response events (if occurred) throughout the surgical procedure
Correlation Between EMG Activity and qCON/qNOX Indices
Relationship between electromyographic (EMG) activity levels and qCON/qNOX index values throughout the procedure. Assessed using correlation analysis between EMG and each index.
Measured: Throughout the surgical procedure (approximately 15-60 minutes)
Index Dynamics During Induction and Emergence from Sedation
Rate of change (slope) in qCON (Quantium Consciousness Index, 0-99 scale), qNOX (Quantium Nociception Index, 0-99 scale), and EMG (electromyographic activity, 0-100 scale) indices during sedation induction and emergence.
Induction phase: from baseline to achievement of target sedation (MOAAS ≤1) Emergence phase: from TCI cessation to return of consciousness (response to verbal commands)
Slopes will be calculated as the rate of index change per unit time (index units per minute) using linear regression for each phase. This standardized measure allows comparison of dynamics across different indices despite their different physiological meanings.
Measured: Induction: 0-10 minutes; Emergence: from TCI stop until recovery of consciousness
Incidence of Pain-Related Motor Responses During Procedural Sedation
Proportion of patients experiencing spontaneous motor responses triggered by noxious stimulation during urological procedures under standardized anesthetic protocol. Motor responses include extremity/trunk movement, facial grimacing, or vocalization.
Measured: During the surgical procedure (approximately 15-60 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start14 Jan 2026
- Primary completion30 Apr 2026 (estimated)
- Study completion30 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Monitoring Noxious Events Using EEG-Derived Pain IndicesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Ankara University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, CIGDEM YILDIRIM GUCLU, Ankara University
- Investigators
- Çiğdem YILDIRIM GÜÇLÜ, MD, Principal investigator, Ankara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07413848
- Sponsor's protocol ID
- 2025/433
- Acronym
- MO-NOX
- Status last verified
- Feb 2026
- First submitted
- 10 Feb 2026
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: De-identified individual participant data are available from the corresponding author upon reasonable request.
Publications
Schuller PJ, Pretorius JPG, Newbery KB. Response of the Conox quantitative electroencephalographic monitor to neuromuscular block in awake volunteers. Br J Anaesth. 2025 Sep;135(3):660-667. doi: 10.1016/j.bja.2025.05.023. Epub 2025 Jul 18.
PubMed 40683805Jensen EW, Valencia JF, Lopez A, Anglada T, Agusti M, Ramos Y, Serra R, Jospin M, Pineda P, Gambus P. Monitoring hypnotic effect and nociception with two EEG-derived indices, qCON and qNOX, during general anaesthesia. Acta Anaesthesiol Scand. 2014 Sep;58(8):933-41. doi: 10.1111/aas.12359. Epub 2014 Jul 4.
PubMed 24995461Linassi F, Vide S, Ferreira A, Schneider G, Gambus P, Kreuzer M. Relationships between the qNOX, qCON, burst suppression ratio, and muscle activity index of the CONOX monitor during total intravenous anesthesia: a pilot study. J Clin Monit Comput. 2024 Dec;38(6):1281-1290. doi: 10.1007/s10877-024-01214-6. Epub 2024 Sep 12.
PubMed 39266928
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Performance of the CONOX Monitor Without Neuromuscular Blockade: qCON and qNOX Responses to Nociceptive Motor Events During Procedural Sedation
- ClinicalTrials.gov ID
- NCT07413848
- Acronym / sponsor ID
- MO-NOX / 2025/433
- Conditions
- Monitoring Noxious Events Using EEG-Derived Pain Indices, Procedural Sedation and Analgesia, Monitored Anesthesia Care
- Keywords
- EEG Monitoring, CONOX Monitor, qNOX Index, qCON Index, Target Controlled Infusion, Procedural Sedation, Propofol
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Ankara UniversityUniversity, hospital or other
- Study start
- 14 Jan 2026 (actual)
- Primary completion
- 30 Apr 2026 (estimated)
- Study completion
- 30 May 2026 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to evaluate whether the CONOX monitor can detect pain during sedation in patients undergoing urological procedures. The main questions it aims to answer are:
Does the qNOX index respond to pain-related motor responses during urological procedural sedation? Does the qNOX index show greater responsiveness to painful episodes compared to blood pressure and heart rate? Participants undergoing urological procedures (such as cystoscopy) under sedation as part of their regular medical care will have continuous brain activity monitoring with the CONOX device. All monitoring displays (CONOX monitor, vital signs monitor, and target-controlled infusion pump) will be video-recorded throughout the procedure to capture synchronized data including qCON, qNOX, EMG, heart rate, blood pressure, oxygen saturation, and drug concentrations. Researchers will analyze the relationship between these indices and spontaneous movements triggered by painful stimulation to evaluate the monitor's performance compared to traditional vital signs.
Detailed description
STUDY RATIONALE
Adequate monitoring of sedation depth and nociception is essential during monitored anesthesia care (MAC). While processed EEG monitors assess hypnotic depth, monitoring pain remains challenging. The CONOX monitor uniquely provides two indices: qCON for sedation depth and qNOX for nociception probability.
Most CONOX studies have used neuromuscular blockade, which prevents motor responses and limits validation of the qNOX index against observable pain reactions. Furthermore, data during procedural sedation and MAC is limited. The absence of neuromuscular blockade during MAC allows studying the relationship between qNOX values and actual pain-triggered motor responses, providing a concrete reference for nociception assessment.
This study evaluates whether an EEG-based nociception index can reliably detect pain when motor responses are not suppressed. If the qNOX index demonstrates adequate performance, it could provide clinicians with a tool for optimizing analgesic administration while minimizing opioid consumption.
STUDY DESIGN
This is a prospective, observational, single-arm cohort study evaluating CONOX monitor performance during procedural sedation without neuromuscular blockade at Ankara University Faculty of Medicine. The study involves no interventions beyond standard clinical care.
The study will enroll 120 adult patients (≥18 years) undergoing elective urological procedures (cystoscopy, ureteroscopy, transurethral resection) under MAC. These procedures involve intermittent painful stimulation and typically do not require neuromuscular blockade. Patient recruitment and data collection will occur over 4 months, followed by 2 months for analysis.
Processed EEG monitoring is part of standard practice in our department. The CONOX monitor will be used for all enrolled patients. The only study-specific procedure is video recording of monitoring displays (not patients) for subsequent analysis.
METHODS
Anesthesia Protocol:
Patients receive standard ASA monitoring. Anesthesia consists of intravenous fentanyl (1 mcg/kg) followed by propofol target-controlled infusion (TCI) using the Eleveld model. Initial target effect-site concentration is 1.5 mcg/mL, titrated to achieve adequate sedation depth (MOAAS ≤1). Patients maintain spontaneous ventilation with airway support as needed. No neuromuscular blockade is used.
Monitoring and Data Collection:
The CONOX monitor continuously records qCON (hypnotic depth), qNOX (nociception), EMG (electromyographic activity), and burst suppression ratio. Standard monitors record ECG, blood pressure, heart rate, SpO₂, and capnography. The TCI pump displays real-time propofol effect-site concentration.
All monitoring displays are video-recorded throughout procedures to capture synchronized data for post-hoc analysis. Researchers provide verbal timestamps to mark clinical events (drug administration, procedure start, motor responses). Videos capture only monitor screens, not patient images.
Primary Endpoint:
The primary endpoint is change in qNOX index from baseline to peak during spontaneous motor responses triggered by surgical stimulation. Motor responses include extremity/trunk movements, facial grimacing, or vocalization, identified by real-time clinical observation.
Data Analysis:
Video recordings are systematically reviewed to extract monitoring values at baseline and during clinical events. For motor response events, peak values and time-to-peak are recorded for each parameter.
STATISTICAL ANALYSIS
Power analysis determined 30 motor response events are required for paired t-test comparing baseline versus peak qNOX (alpha=0.05, power=0.95). Based on estimated 25% incidence and accounting for potential data loss, 120 patients will be enrolled.
Primary analysis uses paired t-test (or Wilcoxon test if non-normal) to compare qNOX at baseline versus during motor responses. ROC curve analysis evaluates discriminative ability of qNOX, heart rate, and blood pressure for predicting motor responses. Secondary analyses include correlation analyses and repeated measures analysis for induction/emergence dynamics. Statistical significance: p<0.05 (two-tailed).
ETHICS AND SAFETY
This observational study involves no interventions beyond standard care. All management decisions follow routine clinical practice. The study has ethics approval from Ankara University Faculty of Medicine Clinical Research Ethics Committee. Written informed consent is obtained from all participants. The study follows Declaration of Helsinki and Good Clinical Practice guidelines.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Procedural Sedation with CONOX Monitoring | – | –Adult patients undergoing elective urological procedures under monitored anesthesia care with continuous CONOX monitoring. All patients receive standard procedural sedation with propofol target-controlled infusion (Eleveld model) and fentanyl (1 mcg/kg), maintaining spontaneous ventilation without neuromuscular blockade. The CONOX monitor continuously records qCON, qNOX, and EMG indices throughout the procedure. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients (≥18 years) scheduled for elective urological procedures under monitored anesthesia care at Ankara University Faculty of Medicine. Patients will undergo standard procedural sedation with propofol target-controlled infusion and fentanyl, maintaining spontaneous ventilation without neuromuscular blockade.
Key inclusion criteria (3 listed)
- Age 18 years or older
- Scheduled for elective diagnostic or therapeutic urological procedures (cystoscopy, ureteroscopy, prostate biopsy, intradetrusor botulinum toxin injection) under monitored anesthesia care
- Able to provide written informed consent
Key exclusion criteria (3 listed)
- Known central neurological disease (epilepsy, Alzheimer's disease, Parkinson's disease, stroke) or history of brain surgery
- Body Mass Index (BMI) ≥35 kg/m²
- Known allergy to anesthetic agents used in the study (propofol, fentanyl, lidocaine)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change from Baseline in Quantium Nociception Index (qNOX) During Motor Responses to Noxious Stimulation
Time frame: During the procedure (approximately 15-60 minutes per patient)
The Quantium Nociception Index (qNOX) is an electroencephalography-derived dimensionless index ranging from 0 to 99. The magnitude of change from baseline to peak qNOX value during spontaneous motor response episodes will be measured. Greater absolute change indicates better discriminative performance of the qNOX index in detecting nociception-evoked motor responses.
4 secondary outcomes
Comparison of qNOX Responsiveness Versus Hemodynamic Parameters During Motor Responses
Time frame: During motor response events (if occurred) throughout the surgical procedure
Correlation Between EMG Activity and qCON/qNOX Indices
Time frame: Throughout the surgical procedure (approximately 15-60 minutes)
Index Dynamics During Induction and Emergence from Sedation
Time frame: Induction: 0-10 minutes; Emergence: from TCI stop until recovery of consciousness
Incidence of Pain-Related Motor Responses During Procedural Sedation
Time frame: During the surgical procedure (approximately 15-60 minutes)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Background: PubMed 40683805Schuller PJ, Pretorius JPG, Newbery KB. Response of the Conox quantitative electroencephalographic monitor to neuromuscular block in awake volunteers. Br J Anaesth. 2025 Sep;135(3):660-667. doi: 10.1016/j.bja.2025.05.023. Epub 2025 Jul 18.
- Background: PubMed 24995461Jensen EW, Valencia JF, Lopez A, Anglada T, Agusti M, Ramos Y, Serra R, Jospin M, Pineda P, Gambus P. Monitoring hypnotic effect and nociception with two EEG-derived indices, qCON and qNOX, during general anaesthesia. Acta Anaesthesiol Scand. 2014 Sep;58(8):933-41. doi: 10.1111/aas.12359. Epub 2014 Jul 4.
- Background: PubMed 39266928Linassi F, Vide S, Ferreira A, Schneider G, Gambus P, Kreuzer M. Relationships between the qNOX, qCON, burst suppression ratio, and muscle activity index of the CONOX monitor during total intravenous anesthesia: a pilot study. J Clin Monit Comput. 2024 Dec;38(6):1281-1290. doi: 10.1007/s10877-024-01214-6. Epub 2024 Sep 12.
- Individual participant dataSharing planned: No. De-identified individual participant data are available from the corresponding author upon reasonable request.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Çiğdem YILDIRIM GÜÇLÜ, MD principal investigator
Ankara University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Monitoring Noxious Events Using EEG-Derived Pain Indices and Procedural Sedation and Analgesia, run by Ankara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cahit Sefer Uçar, MD (+905532774107, cs.ucar@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Quantium Nociception Index (qNOX) During Motor Responses to Noxious Stimulation (time frame: During the procedure (approximately 15-60 minutes per patient)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07413848, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.